CWIAX
Price
$82.59
Change
+$0.54 (+0.66%)
Updated
Jun 2 closing price
Net Assets
151.89B
VICEX
Price
$23.12
Change
+$0.31 (+1.36%)
Updated
Jun 2 closing price
Net Assets
52.22M
Interact to see
Advertisement

CWIAX vs VICEX

Header iconCWIAX vs VICEX Comparison
Open Charts CWIAX vs VICEXBanner chart's image
CWIAX vs VICEX Comparison Chart in %
View a ticker or compare two or three
VS
CWIAX vs. VICEX commentary
Jun 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CWIAX is a Buy and VICEX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
CWIAX has more cash in the bank: 152B vs. VICEX (52.2M). CWIAX pays higher dividends than VICEX: CWIAX (1.33) vs VICEX (1.02). CWIAX was incepted earlier than VICEX: CWIAX (24 years) vs VICEX (24 years). VICEX (1.91) is less costly to investors than CWIAX (0.75). CWIAX is a more actively managed with annual turnover of: 44.00 vs. VICEX (14.00). CWIAX has a lower initial minimum investment than VICEX: CWIAX (250) vs VICEX (2000). CWIAX annual gain was more profitable for investors over the last year : 22.44 vs. VICEX (-0.60). CWIAX return over 5 years is better than : 38.19 vs. VICEX (-27.30).
CWIAXVICEXCWIAX / VICEX
Total Expense Ratio0.751.7343%
Annual Report Gross Expense Ratio0.751.9139%
Fund Existence24 years24 years-
Gain YTD15.6525.602279%
Front Load4%N/A-
Min. Initial Investment250200013%
Min. Initial Investment IRAN/AN/A-
Net Assets152B52.2M291,188%
Annual Yield % from dividends1.331.02130%
Returns for 1 year22.44-0.60-3,744%
Returns for 3 years54.65-0.74-7,420%
Returns for 5 years38.19-27.30-140%
Returns for 10 years122.63-22.38-548%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CSHAX12.600.20
+1.61%
NYLI Cushing® MLP Premier Class A
JCPRX25.76N/A
N/A
JPMorgan US Large Cap Core Plus R5
OIEIX26.19N/A
N/A
JPMorgan Equity Income A
RYBOX65.18N/A
N/A
Rydex Biotechnology A
PSKCX23.33N/A
N/A
Virtus KAR Mid-Cap Growth C